BRÈVE

sur Jaguar Health (NASDAQ:JAGX)

Jaguar Health Strengthens IP Protection with New European and Australian Patents

Graphique de l'évolution du cours de l'action Jaguar Health (EBR:JAGX).

Jaguar Health, Inc. (NASDAQ:JAGX) has announced the issuance of new patents in Europe and Australia, enhancing the company's intellectual property protection for crofelemer. Crofelemer is a plant-based prescription drug targeting rare disease indications such as Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDDs), specifically microvillus inclusion disease (MVID).

The European patent covers methods for treating SBS, bile acid diarrhea, and diarrhea related to small intestine resection or gallbladder removal with chloride-ion transport inhibitors like crofelemer. In Australia, the new patent covers methods for preventing and treating diarrhea associated with CDDs using crofelemer.

Lisa Conte, Jaguar's CEO, emphasized that these new patents further solidify crofelemer's IP protection. Jaguar Health is supporting proof-of-concept studies for crofelemer in regions including the US, EU, and MENA, with results expected in 2024 and 2025. The studies aim to offer early patient access based on specific EU country guidelines.

R. P.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Jaguar Health